Incidence and risk of arterial and venous thrombotic events in Systemic Lupus Erythematosus patients: a population-based study.
Luisa Ojeda-FernándezStefania CalvisiGinevra TorrigianiMauro TettamantiIda FortinoMaria Carla RoncaglioniMarta BavieraPublished in: Rheumatology (Oxford, England) (2024)
Our findings confirmed higher risks of ATE, VTE and all-cause death in SLE patients. While increased CV medications use after SLE diagnoses suggests heightened awareness to CV risk profile, more attention is required to balance SLE disease activity with minimizing exposure to drugs associated with exacerbating CV risk.
Keyphrases
- disease activity
- systemic lupus erythematosus
- end stage renal disease
- rheumatoid arthritis
- chronic kidney disease
- ejection fraction
- newly diagnosed
- prognostic factors
- ankylosing spondylitis
- rheumatoid arthritis patients
- peritoneal dialysis
- venous thromboembolism
- working memory
- risk factors
- juvenile idiopathic arthritis
- patient reported outcomes